Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01150487 |
|
Recruitment Status :
Recruiting
First Posted : June 25, 2010
Last Update Posted : March 14, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Sensitized Post Kidney Transplant Recipients | Procedure: bone marrow aspirations | Not Applicable |
The aim of this risk protocol is to determine the variability of the AlloElispot and Allospecificities assay.
Our group has developed two novel assays to determine: 1) the number of donor-specific alloantibody (DSA) secreting bone marrow derived plasma cells (AlloELISPOT assay); and 2) the function of DSA-secreting Plasma cells (Allospecificities assay).
These assays were developed over the past 3 years and already have provided an important means of testing new therapeutic protocols aimed at controlling DSA production. It is important to note that repeated attempts to isolate PCs from peripheral blood have been unsuccessful (PCs are extremely rare in peripheral blood) and the bone marrow is the only accessible source of PCs.
It is now clear to that we have reached a point that we must validate these assays (coefficient of variation, etc), in order to appropriately evaluate data derived from these assays. Inter-assay variability can be assessed by performing two paired assays in the same patient. This could be done in two ways—paired bone marrow aspirations separated by time or two bone marrow aspirations performed at the same time. We have decided to pursue the latter approach. We will do both marrows either at the time of transplantation when the subjects are under general anesthesia or in the Clinical Research Unit (CRU) using conscious sedation.. We believe that this is safe and will be well-tolerated and will provide the data that we need to validate the assays.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 80 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Paired Bone Marrow Aspirations to Assess the Variability of Allo-ELISPOT and Allo-Specificities Assays in Sensitized Renal Allograft Recipients |
| Study Start Date : | June 2010 |
| Estimated Primary Completion Date : | April 2020 |
| Estimated Study Completion Date : | October 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Sensitized Renal Allograft Recipients
Patients who have antibodies against their donors in their blood.
|
Procedure: bone marrow aspirations
A bone marrow aspiration from each hip bone of the patients. |
- To determine the variability of the AlloElispot and Allospecificities assay. [ Time Frame: Post bone marrow collection ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion criteria.
- Pre or post renal transplant recipients who are "sensitized", having allo antibodies as evidenced by single antigen bead analysis).
- Renal transplant donors.
- Those who give voluntary written informed consent before performance of any study-related procedures, which are not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
Exclusion criteria.
- Any patient currently receiving systemic anticoagulation therapy with heparin or coumadin.
- Patient has a platelet count of <30 x 10(9)/L within 14 days before enrollment.
- Patient has an absolute neutrophil count of ANC<1.0 x 10(9)/L within 14 days before enrollment.
- Patient has received other investigational drugs within14 days before enrollment.
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- Diagnosed or treated for malignancy within 5 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
- Contraindication to kidney transplantation or donation—active infection, comorbid medical conditions, etc
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01150487
| Contact: Nong Yowe Braaten | 507-538-9617 |
| United States, Minnesota | |
| Mayo Clinic | Recruiting |
| Rochester, Minnesota, United States, 55905 | |
| Contact: Nong Yowe Braaten 507-538-9617 | |
| Principal Investigator: Mark Stegall, MD | |
| Principal Investigator: | Mark Stegall, MD | Mayo Clinic |
Additional Information:
| Responsible Party: | Mark Stegall, Consultant, Mayo Clinic |
| ClinicalTrials.gov Identifier: | NCT01150487 |
| Other Study ID Numbers: |
10-002572 |
| First Posted: | June 25, 2010 Key Record Dates |
| Last Update Posted: | March 14, 2019 |
| Last Verified: | March 2019 |
|
kidney transplant |